CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project trains early-stage researchers in tuberculosis drug discovery, focusing on developing inhibitors for new drug targets. The researchers will gain experience in both academic and industrial settings, contributing to the fight against drug-resistant tuberculosis.
We propose a PhD programme for 4 Early-Stage Researchers (ESR) in tuberculosis (TB) drug discovery.
Often associated with poverty, TB is rampant in many parts of Africa and Asia but has now also returned to developed nations.
Growing resistance against currently used antibiotics is one of the most pressing problems of the global TB epidemic.
Treating TB infections requires a drug cocktail given for at least 6 months, extending to 2 years for infections with multi-drug resistant strains of Mycoba…
THE UNIVERSITY OF BIRMINGHAM
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Tres Cantos
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
